Today: 11 June 2026
Rocket Lab stock rebounds as year-end turbulence keeps Space Force contract in focus

Rocket Lab stock rebounds as year-end turbulence keeps Space Force contract in focus

NEW YORK, December 29, 2025, 10:17 ET — Regular session

  • Rocket Lab shares rose about 2.4% in early New York trading, recovering some of Friday’s sharp drop.
  • Investors continued to focus on the company’s $816 million Space Development Agency satellite award signed earlier this month.
  • Broader U.S. indexes slipped as heavyweight tech stocks retreated in holiday-thinned trading.

Rocket Lab Corp shares rose 2.4% to $72.36 by 10:11 a.m. ET on Monday, a bounce after last week’s sharp swings.

The move matters because Rocket Lab’s stock has been whipsawed by defense-contract headlines into year-end, a period when thin volumes can exaggerate price moves. Shares jumped 17.7% on Dec. 19 and nearly 10% on Dec. 22 before sliding 8.5% on Friday, historical pricing showed.

Investors are still digesting what the company’s latest Space Development Agency award could mean for Rocket Lab’s push beyond its small-launch roots into higher-value national security satellite work. The company builds and launches the Electron rocket and sells spacecraft and satellite components.

Rocket Lab ended Friday at $70.65 after hitting an intraday high of $79.83 on Dec. 24, near a record, according to historical quotes.

A Dec. 17 agreement with the Space Development Agency carries a total value of $816 million, including a $806 million base and $10 million of options, a regulatory filing showed. Work begins immediately, with final delivery of the satellites for launch expected in 2029.

The agreement allows either party to terminate “for convenience,” a provision that can let a customer end a contract without alleging breach, subject to conditions in the agreement, the filing said. SEC

The satellite win is part of a larger Space Development Agency push. The agency said it reached agreements worth about $3.5 billion collectively with Lockheed Martin, L3Harris Technologies, Northrop Grumman and Rocket Lab to build 72 infrared satellites, with each supplier contracted for 18 spacecraft.

The contracts are fixed-price, meaning the contractor agrees to deliver work for a set amount, leaving cost overruns more likely to pressure margins. The satellites are expected to be launched into low-Earth orbit in 2029, Reuters reported.

Rocket Lab said the Tracking Layer satellites will carry its Phoenix infrared sensor payload and its StarLite space protection sensors, and it flagged additional subsystem opportunities that “could take the total capture value to approximately $1 billion.” GlobeNewswire

“Rocket Lab is honored to play a role in enabling this,” founder and CEO Peter Beck said in the Dec. 19 release. GlobeNewswire

Rocket Lab’s gain came as U.S. indexes slipped. The Nasdaq Composite was down about 0.6% around 9:35 a.m. ET as technology shares pulled back, Reuters reported.

Traders are now watching whether Rocket Lab can hold above the $70 area — near Friday’s close — while the stock remains below last week’s $79.83 intraday peak.

Next catalysts include quarterly results expected in late February, with MarketBeat estimating Feb. 26 after the market close and noting the company has not confirmed a date. Launch trackers list Rocket Lab’s next Electron mission in January 2026, though schedules are subject to change.

Stock Market Today

  • Top Software Stocks Set for Rally in Second Half, Says BofA
    June 11, 2026, 11:15 AM EDT. Bank of America (BofA) has identified leading software stocks poised for a significant rally in the second half of the year. While specific companies were not detailed, BofA's outlook highlights growth potential in the tech sector amid evolving market conditions. Investors are closely watching software firms as demand for digital solutions continues to expand, driven by cloud computing and enterprise software trends. This bullish stance from a major financial institution underscores confidence in software stocks as key components of portfolio growth strategies moving forward.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386
Previous Story

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

MongoDB stock slides as “MongoBleed” exploitation warning puts database security in focus
Next Story

MongoDB stock slides as “MongoBleed” exploitation warning puts database security in focus

Go toTop